Proceeds from the placement will be used for general corporate and working capital purposes, including commercialization of the firm's ICE COLD-PCR technology.
The partners will augment the multiplexing capabilities of ICE COLD-PCR, which was developed at Dana-Farber and is exclusively licensed to Transgenomic.
The lower sales from contract laboratory services reflect Transgenomic's continued refocusing on its core ICE-COLD PCR molecular diagnostic technology.
Adstec will assume the business, financial, and human resource commitments of the business and pay Transgenomic $300,000 for stock and inventory related to the business.
The deal covers four of Transgenomic's liquid biopsy cancer assays, which detect actionable mutations associated with sensitivity or resistance to therapy.
The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.
The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.
Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.
